The FDA has approved Zoryve, a once-daily steroid-free foam, for the treatment of seborrheic dermatitis in individuals aged 9 years and older. This makes Zoryve the first drug approved for this condition with a new mechanism of action in over 20 years. The approval was supported by positive results from the STRATUM phase 3 trial, with 79.5% of patients treated with Zoryve achieving the primary endpoint of IGA success compared with 58% of vehicle-treated patients. Zoryve also showed rapid itch relief and a favorable safety profile for up to 52 weeks of treatment. The drug will be available to wholesalers and dermatology pharmacy channels by the end of January 2024.
Source link
FDA approves Zoryve for treatment of seborrheic dermatitis
